Add Feed
News Archives
2006
NanoMed Pharmaceuticals Closes Initial Financing
KALAMAZOO, MI., (July 5, 2006) - NanoMed Pharmaceuticals, Inc., an advanced drug delivery company developing nanoparticle-based therapeutic and diagnostic products to treat or detect disease, announced today that it has closed on its first round of venture financing. The investment was led by the SWMF Life Science Venture Fund, a $50 million private equity fund investing exclusively in promising life science companies having a presence in the Kalamazoo Region. Read More...
NanoMed Pharmaceuticals Awarded STTR for Nanotemplate Engineering of a Novel Molecular Imaging Agent
KALAMAZOO, MI., (September 7, 2006) - NanoMed Pharmaceuticals, Inc., an advanced drug delivery company developing nanoparticle-based therapeutic and diagnostic products to treat or detect disease, announced today that it has been awarded a Small Business Technology Transfer (STTR) grant by the National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering for "Nanotemplate Engineering of a Stealth MRI Contrast Agent." The work funded by this Phase I grant will be completed at the company's laboratory located in the University of Kentucky's Advanced Science & Technology Commercialization Center. Read More...
NanoMed Pharmaceuticals Awarded STTR to Further Develop Botanical Drug for Oral Cancer Chemoprevention
KALAMAZOO, MI., (September 13, 2006) - NanoMed Pharmaceuticals, Inc., an advanced drug delivery company developing therapeutic and diagnostic products to treat or detect disease, announced today that it has been awarded a Small Business Technology Transfer (STTR) grant by the National Institutes of Health, National Center for Complimentary and Alternative Medicine, for "Bioadhesive Gels for Oral Cancer Chemoprevention." The work funded by this Phase I grant will be completed at the company's laboratory located in the University of Kentucky's Advanced Science & Technology Commercialization Center, and in collaboration with researchers at the University of Kentucky and The Ohio State University. Read More...
Jay Named AAPS Fellow
Monday, October 09, 2006 - Michael Jay, Ph.D., professor of pharmaceutical sciences and director of the Center for Pharmaceutical Science and Technology (CPST) at the University of Kentucky College of Pharmacy, will be conferred as Fellow of the American Association of Pharmaceutical Scientists (AAPS) at the organization's annual meeting in San Antonio, Oct. 29 - Nov. 2. Read More...
Mumper to Recieve AAPs Drug Delivery Systems Award
Monday, October 09, 2006 - Russ Mumper, Ph.D., associate professor and vice chair of the University of Kentucky Department of Pharmaceutical Sciences at the UK College of Pharmacy, will be awarded the 2006 American Association of Pharmaceutical Scientists (AAPS) Lipids-Based Drug Delivery Systems Award sponsored by Gattefosse during the upcoming AAPS meeting in San Antonio Oct. 29-Nov. 2. The award recognizes outstanding research, pertaining to lipids and their role in drug delivery. Read More...
Nanoparticles Overcome Anticancer Drug Resistance
(June 12, 2006) Too often, chemotherapy fails to cure cancer because some tumor cells develop resistance to multiple anticancer drugs. In most cases, resistance develops when cancer cells begin expressing a protein, known as p-glycoprotein, that is capable of pumping anticancer drugs out of a cell as quickly as they cross through the cell's outer membrane. New research from the University of Kentucky shows that nanoparticles may be able to get anticancer drugs into cells without triggering the p-glycoprotein pump.
NanoMed Pharmaceuticals Founder Work Cited by NCI Alliance for Nanotechnology in Cancer
(June 12, 2006) Too often, chemotherapy fails to cure cancer because some tumor cells develop resistance to multiple anticancer drugs. In most cases, resistance develops when cancer cells begin expressing a protein, known as p-glycoprotein, that is capable of pumping anticancer drugs out of a cell as quickly as they cross through the cell's outer membrane. New research from the University of Kentucky shows that nanoparticles may be able to get anticancer drugs into cells without triggering the p-glycoprotein pump.
NanoMed Pharmaceuticdals Profiled in Windhover's "Start-Up"
(June, 2006) NanoMed Phermaceuticals Profiled in Windhover's "Start-Up"NanoMed Pharma Moves To Kalamazoo, Mich. With Series A
VENUTREWIRE
Kalamazoo, Mich. (Thursday, July 6, 2006) -- NanoMed Pharmaceuticals Inc., a developer of a nanoparticle manufacturing technology for treating patients undergoing chemotherapy, said that it has closed on a Series A preferred round of venture financing.
The sole investor in the round was the Southwest Michigan First (SWMF) Life Science Venture Fund, which invests in life science companies in the Kalamazoo, Mich. area.
With the funding, NanoMed will move its headquarters from Lexington, Ky. to the Michigan Technical Education Center in Kalamazoo, Mich. The company's laboratories will be located in the Advanced Science & Technology Commercialization Center at the University of Kentucky.
